Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Probiotics Antimicrob Proteins ; 16(2): 367-382, 2024 Apr.
Article in English | MEDLINE | ID: mdl-36884184

ABSTRACT

Probiotics play a crucial role in immunomodulation by regulating dendritic cell (DC) maturation and inducing tolerogenic DCs. Akkermansia muciniphila affects inflammatory response by elevating inhibitory cytokines. We aimed to evaluate whether Akkermansia muciniphila and its outer membrane vesicles (OMVs) affect microRNA-155, microRNA-146a, microRNA-34a, and let-7i expression of inflammatory and anti-inflammatory pathways. Peripheral blood mononuclear cells (PBMCs) were isolated from the healthy volunteers. To produce DCs, monocytes were cultivated with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). DCs were allocated into six subgroups: DC + Lipopolysaccharide (LPS), DC + dexamethasone, DC + A. muciniphila (MOI 100, 50), DC + OMVs (50 µg/ml), and DC + PBS. The surface expression of human leukocyte antigen-antigen D related (HLA-DR), CD86, CD80, CD83, CD11c, and CD14 was examined using flow cytometry, and the expression of microRNAs was assessed using qRT-PCR, and the levels of IL-12 and IL-10 were measured using ELISA. A. muciniphila (MOIs 50, 100) could significantly decrease IL-12 levels relative to the LPS group. The IL-10 levels were decreased in the DC + LPS group than the DC + dexamethasone group. Treatment with A. muciniphila (MOI 100) and OMVs could elevate the concentrations of IL-10. DC treatment with LPS led to a significant increment in the expression of microRNA-155, microRNA-34a, and microRNA-146a. The expression of these microRNAs was reversed by A. muciniphilia and its OMVs treatment. Let-7i increased in treatment groups compared to the DC + LPS group. A. muciniphilia (MOI 50) had a substantial effect on the expression of HLA-DR, CD80, and CD83 on DCs. Therefore, DCs treatment with A. muciniphila led to induce tolerogenic DCs and the production of anti-inflammatory IL-10.


Subject(s)
Interleukin-10 , MicroRNAs , Humans , Interleukin-10/genetics , Leukocytes, Mononuclear , Lipopolysaccharides/pharmacology , Cells, Cultured , Interleukin-12/metabolism , Interleukin-12/pharmacology , MicroRNAs/genetics , MicroRNAs/metabolism , B7-1 Antigen/analysis , B7-1 Antigen/metabolism , B7-1 Antigen/pharmacology , Monocytes , HLA-DR Antigens/analysis , HLA-DR Antigens/metabolism , HLA-DR Antigens/pharmacology , Anti-Inflammatory Agents/pharmacology , Dexamethasone/pharmacology , Dexamethasone/metabolism , Dendritic Cells , Akkermansia
2.
Int Immunopharmacol ; 84: 106573, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32454410

ABSTRACT

Brucellosis is the most common zoonotic disease worldwide and still there is no vaccine for human use. The commercial animal vaccines also have major problems that limit their use. Therefore, there is a need for an effective Brucella vaccine which is multivalent and produces a good protective immunity with minimal disadvantages. Due to their heterogeneous composition and diverse functions, OMVs are promising acellular vaccine candidates against brucellosis. In the present study, the potential of Poly(I:C) or CpG ODN 1826+ Montanide ISA 70 VG adjuvant formulations were evaluated to enhance the immunity and protection levels conferred by OMVs against Brucella challenge in mice. The results indicated that both vaccine regimens were able to induce strong Th1-biased responses and confer protective levels significantly higher than REV.1 live vaccine. With regard to the results, it is concluded that OMVs in either adjuvant can be introduced as a new vaccine candidate against B. melitensis infection.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Bacterial Outer Membrane/immunology , Brucella Vaccine/administration & dosage , Brucellosis/prevention & control , Cell Membrane Structures/immunology , Mannitol/analogs & derivatives , Oleic Acids/administration & dosage , Oligodeoxyribonucleotides/administration & dosage , Poly I-C/administration & dosage , Animals , Brucella melitensis/drug effects , Brucella melitensis/growth & development , Cytokines/immunology , Female , Immunoglobulin G/immunology , Mannitol/administration & dosage , Mice, Inbred BALB C
3.
Curr HIV Res ; 9(4): 263-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21671883

ABSTRACT

Chronic hepatitis B affects nearly 10% of HIV-infected patients. Hepatitis B virus (HBV) infection is a dynamic disease and coinfection with HIV impacts directly on the outcome of HBV infection, considerably complicating its natural history, diagnosis, and management. The aim of this study was to compare two cohorts of HBV monoinfected and HBV/HIV coinfected Iranian patients undergoing long-term lamivudine therapy from the clinical and virological aspects, as well as the frequency of detected mutations in HBV genome. To this end, HBV Pol/S regions from 72 patients were PCR-amplified and directly sequenced. Phylogenetic analysis indicated a 40-times higher risk of coinfection with ayw3 subtype of HBV genotype D rather than ayw2 subtype [P<0.001, odd: 40.66, CI: 95 % (4.69-352.23)]. While no resistance mutation was detected in HBV/HIV coinfected cohort, LAM-resistance mutations (rtM204I/V in YMDD and rtL180M in FLLA polymerase motifs) were identified in 30% (9 out of 30) and 16.66% (5 out of 30) of HBV monoinfected patients (P<0.05). Moreover, several mutations (sP105A, sI110S/L, sS136Y and sP127T/L) with significant differences in the frequency were identified in the S region of both cohorts. Finally, this study found strong correlation between the type of infection (mono or coinfection) and characteristics like patient gender, ALT levels, HBV-DNA levels and HBV subtypes. These results pointed to the importance of determination of HBV variants in the management of patients and suggested that in contrary to HBV monoinfections, LAM may be still an appropriate drug for the treatment of HBV in HBV/HIV coinfected patients; however, further studies to clarify the role of HIV in HBV LAM-resistance mutations are required.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Hepatitis B virus/genetics , Hepatitis B/drug therapy , Hepatitis B/virology , Lamivudine/therapeutic use , Adult , Cohort Studies , DNA Mutational Analysis , DNA-Directed DNA Polymerase/genetics , Drug Resistance, Viral/genetics , Female , Gene Frequency , Genotype , HIV Infections/complications , HIV Infections/virology , Hepatitis B/complications , Humans , Iran , Male , Mutation/genetics , Phylogeny
4.
Obstet Gynecol ; 116 Suppl 2: 526-528, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20664442

ABSTRACT

BACKGROUND: Pyomyoma (suppurative leiomyoma) is a rare disease that is a serious complication. Most cases have occurred in pregnant or postmenopausal women. CASE: A perimenopausal woman presented with fever and shoulder pain. She had no predisposing factors or history of leiomyoma. Ultrasonographic as well as abdominal and pelvic computed tomography scans showed an enlarged uterus with two large masses. Internal heterogeneous echogenicity was noted in the lower segment and body of the uterus. The elevated temperature continued despite a 3-day antibiotic course of clindamycin, ceftriaxone, and gentamicin. With a clinical impression of infected leiomyoma, she underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy. Pathological findings showed a leiomyoma with abscess formation. The patient responded well to surgery. CONCLUSION: Pyomyoma may be difficult to diagnose, especially in women with a nonspecific clinical presentation. Delayed diagnosis may result in serious complications, and surgery and broad spectrum antibiotics are indicated.


Subject(s)
Abscess/therapy , Citrobacter , Enterobacteriaceae Infections/complications , Fever of Unknown Origin/etiology , Leiomyoma/therapy , Uterine Neoplasms/therapy , Abscess/microbiology , Anti-Bacterial Agents/therapeutic use , Enterobacteriaceae Infections/microbiology , Female , Gynecologic Surgical Procedures , Humans , Leiomyoma/microbiology , Middle Aged , Premenopause , Uterine Neoplasms/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...